Skip to main content

Table 2 ERβ1 expression levels by morphology and subtype

From: ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer

  ERβ1 expression Cohort 1 n = 184** Cohort 2 n = 68 n = 177
   Nucleus Cytoplasm Nucleus Cytoplasm Nucleus Cytoplasm
Molecular Subtype
  Luminal A (ERα +/ HER2 -/ Ki67 ≤ 10) Neg/low 31 (18.3) 47 (25.5)     
Moderate 18 (10.7) 3 (1.6)     
High 1 (0.6) 0     
  Luminal B (ERα +/ HER2 -/ Ki67 > 10) Neg/low 59 (34.9) 76 (41.3)     
Moderate 25 (14.8) 11 (6.0)     
High 3 (1.8) 0     
  Her2+ Neg/low 20 (11,8) 24 (13.0)     
Moderate 7 (4.1) 3 (1.6)     
High 0 0     
  Triple Negative (ERα -/PR-/ HER2 -) Neg/low 1 (0.6) 5 (2.7) 51 (75.0) 45 (66.2)   
Moderate 4 (2.4) 0 17 (25.0) 21 (30.9)   
High 0 0 0 2 (2.9)   
Histologic Subtype
Ductal Neg/low 93 (50.5) 120 (65.2) 39 (57.4) 34 (50.0) 28 (15.8) 0
Moderate 42 (22.8) 18 (9.8) 13 (19.1) 16 (23.5) 79 (44.6) 45 (25.4)
High 3 (1.6) 0 0 2 (2.9) 36 (20.3) 98 (55.4)
Lobular Neg/low 18 (9.8) 26 (14.1) 0 0 1 (0.6) 0
Moderate 9 (4.9) 2 (1.1) 0 0 10 (5.7) 3 (1.7)
High 1 (0.5) 0 0 0 5 (2.8) 13 (7.3)
Other Neg/low 10 (5.4) 18 (9.8) 12 (17.6) 11 (16.2) 3 (1.7) 1 (0.6)
Moderate 8 (4.4) 0 4 (5.9) 5 (7.4) 7 (4.0) 4 (2.3)
  High 0 0 0 0 8 (4.5) 13 (7.3)
  1. *ki67 not performed **unable to determine molecular subtype in 15 Cohort 1 pts.
\